Akari Therapeutics, Plc
Akari Therapeutics, Plc, a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for rare and complex diseases. Founded in 2014, Akari has made significant strides in the industry, particularly in the fields of immunology and rare genetic disorders. The company is renowned for its unique approach to harnessing the power of its proprietary complement inhibitors, which target the underlying mechanisms of disease. Akari's flagship product, designed to address unmet medical needs, showcases its commitment to advancing patient care. With a strong market position, Akari Therapeutics continues to achieve notable milestones, positioning itself as a leader in the biopharmaceutical landscape. Its dedication to research and development underscores its mission to transform the lives of patients worldwide.
DitchCarbon Score
How does Akari Therapeutics, Plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akari Therapeutics, Plc's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akari Therapeutics, Plc's reported carbon emissions
Akari Therapeutics, Plc, headquartered in the US, currently does not have any reported carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Akari Therapeutics may not yet have established formal commitments to carbon emissions reduction or sustainability initiatives. In the context of the biopharmaceutical industry, many companies are increasingly focusing on climate commitments and emissions reductions, often setting targets aligned with the Science Based Targets initiative (SBTi) or participating in global climate pledges. However, without specific data or commitments from Akari Therapeutics, it is unclear how they align with these industry standards. As the company progresses, it may consider developing a framework for measuring and reporting its carbon footprint, as well as setting ambitious targets to contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akari Therapeutics, Plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
